title: Herpesvirus vectors for therapy of brain tumors.
abstract: Genetically modified, conditionally-replicating Herpes Simplex Virus Type 1 (HSV-1) vectors for the treatment of malignant glioma have provided encouraging results in the handful of Phase I and Phase II clinical trials conducted to date. In recent years, a number of new strategies have been developed to improve anti-tumor activity of these attenuated vectors, through either introduction of foreign gene inserts to enhance tumor killing through a variety of mechanisms, or through combination with existing treatment regimens, including radiation and/or chemotherapeutics. Another promising new approach has been the engineering of novel oncolytic HSV vectors that retain wildtype replication, but are targeted to tumor cells through a variety of mechanisms. This review summarizes the latest advances in herpesvirus-mediated oncolytic therapies from both preclinical results and clinical trials with oncolytic HSV vectors in patients, and their implication for design of future trials.
authors.affiliation: Department of Pediatrics, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294-0011, USA.
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Cassady
authors.forename: Jacqueline Nuss
authors.initials: JN
authors.lastname: Parker
references.citation: Surgery. 2002 Aug;132(2):353-9
references.pmid: 12219034
references.citation: Gene Ther. 2004 Nov;11(22):1648-58
references.pmid: 15334111
references.citation: Neurotherapeutics. 2009 Jul;6(3):558-69
references.pmid: 19560745
references.citation: J Gen Virol. 1974 Sep;24(3):465-80
references.pmid: 4372299
references.citation: Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13
references.pmid: 10681459
references.citation: Proc Natl Acad Sci U S A. 1989 Jun;86(12):4736-40
references.pmid: 2543985
references.citation: Cancer Res. 2005 Oct 15;65(20):9479-84
references.pmid: 16230412
references.citation: Gene Ther. 2000 May;7(10):859-66
references.pmid: 10845724
references.citation: Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3266-70
references.pmid: 1314384
references.citation: J Biol Chem. 1998 Aug 14;273(33):20737-43
references.pmid: 9694816
references.citation: Science. 1991 May 10;252(5007):854-6
references.pmid: 1851332
references.citation: Virology. 1988 Sep;166(1):41-51
references.pmid: 2842955
references.citation: Gene Ther. 2000 May;7(10):867-74
references.pmid: 10845725
references.citation: Nat Cell Biol. 2001 Aug;3(8):745-50
references.pmid: 11483960
references.citation: Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):637-46
references.pmid: 17011442
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5508-13
references.pmid: 16554374
references.citation: Hum Gene Ther. 2007 Jan;18(1):63-73
references.pmid: 17238803
references.citation: Cancer Gene Ther. 2006 Mar;13(3):326-34
references.pmid: 16138120
references.citation: Neurotherapeutics. 2009 Jul;6(3):547-57
references.pmid: 19560744
references.citation: Clin Cancer Res. 1999 May;5(5):985-90
references.pmid: 10353730
references.citation: J Virol. 2004 Jan;78(1):197-205
references.pmid: 14671101
references.citation: Expert Rev Neurother. 2009 Oct;9(10):1519-27
references.pmid: 19831841
references.citation: J Virol. 2005 May;79(9):5272-7
references.pmid: 15827141
references.citation: J Virol. 2005 Jul;79(14):8707-15
references.pmid: 15994764
references.citation: Gene Ther. 1998 Feb;5(2):160-5
references.pmid: 9578834
references.citation: Curr Gene Ther. 2009 Oct;9(5):341-55
references.pmid: 19860649
references.citation: Cancer Res. 1994 Nov 15;54(22):5745-51
references.pmid: 7954393
references.citation: Cancer Res. 2005 Apr 1;65(7):2832-9
references.pmid: 15805284
references.citation: Front Biosci. 2008 Jan 01;13:2060-4
references.pmid: 17981691
references.citation: Science. 1990 Nov 30;250(4985):1262-6
references.pmid: 2173860
references.citation: Expert Rev Neurother. 2009 Apr;9(4):505-17
references.pmid: 19344302
references.citation: Mol Ther. 2009 Jan;17(1):199-207
references.pmid: 18957964
references.citation: J Neurooncol. 2003 Dec;65(3):203-26
references.pmid: 14682372
references.citation: Mol Ther. 2008 Nov;16(11):1783-8
references.pmid: 18728637
references.citation: Gene Ther. 2002 Mar;9(6):398-406
references.pmid: 11960316
references.citation: J Natl Cancer Inst. 2006 Jan 4;98(1):38-50
references.pmid: 16391370
references.citation: Neoplasia. 2002 Sep-Oct;4(5):388-99
references.pmid: 12192597
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: Gene Ther. 2007 Jul;14(13):1045-54
references.pmid: 17429445